Hims & Hers Health stock tanks
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
India Today on MSN43m
Meta CEO designs minivan for wife. Shows off his 'his and hers' Porsches
Zuckerberg posted photos and videos of a Porsche 911 GT3 with a touring package for himself, and a customised Porsche Cayenne ...
What's on Netflix3d
‘His & Hers’ Netflix Limited Series: Filming Underway & Everything We Know So Far
Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.
Hims & Hers: The Gift That Keeps On Giving
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
Another Today Exit Was Allegedly Coming Before Hoda Announced Hers. Now NBC Is Apparently Hanging On Tightly
When you buy through links on our articles, Future and its syndication partners may earn a commission.
USPS mail carrier arrested for shoplifting at Buc-ee’s, stealing debit cards from mail that wasn’t hers, police say
A United States postal worker is facing multiple theft charges, including opening mail that didn’t belong to her, after ...
2 Winning Growth Stocks That Are Screaming Buys Right Now
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
These Stocks Moved the Most Today: EVgo, Levi Strauss, Humana, Hims & Hers, Nvidia, Tesla, Vistra, and More
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.